THE RELATIONSHIP BETWEEN sTREM-1 AND ACTIVATION OF INFLAMMATORY BOWEL DISEASES

Yıl 2021, Cilt: 84 Sayı: 3, 318 - 323, 31.07.2021

Yasin Kutlu İlkim Deniz Toprak Yasemin Gökden Hasan Eruzun Yücel Arman Şengül Aydın Yoldemir Zeki Toprak Tufan Tükek

Öz

Objective: In inflammatory bowel disease (IBD), there is no reliable biomarker, yet. We aimed to determine whether Serum Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) could be useful as a marker for the diagnosis and/or the determination of disease activity in patients with IBD. Material and Method: A total of 47 patients with ulcerative colitis (UC) and 25 patients with Crohn’s disease (CD) were prospectively enrolled. Clinical disease activity was analyzed using the Crohn’s Disease Activity Index (CDAI) for CD and the Truelove- Witts index for UC. Results: sTREM-1 levels were significantly lower in patients with IBD compared to healthy controls (p=0.001). In comparison of the levels of sTREM-1 between the different groups (CD, UC, and healthy controls) the difference was statistically significant. No considerable differences in sTREM-1 levels were determined in patients with active versus quiescent disease. The sTREM-1 levels negatively correlated with C-reactive protein, blood neutrophil- lymphocyte ratio, and positively with haemoglobin levels. Conclusion: sTREM-1 levels are decreased in IBD patients compared with the healthy individuals. It may, therefore, be useful for the diagnosis of IBD. However, it does not seem to be a precise marker of disease activity in IBD and cannot be suggested for assessing disease activity in these patients.

Anahtar Kelimeler

sTREM-1, inflammatory bowel diseases, Crohn’s disease, ulcerative colitis

İNFLAMATUAR BARSAK HASTALIKLARI AKTİVASYONU İLE sTREM-1 ARASINDAKİ İLİŞKİ

Öz

Amaç: İnflamatuar barsak hastalıkları (İBS) tanısında henüz uygun bir biyobelirteç bulunmamıştır. Çalışmamızda STREM-1 molekülünün bir belirteç olarak, İBS tanısında ve hastalık aktivitesini belirlemede uygunluğunu belirlemeyi amaçladık. Gereç ve Yöntem: Toplam 47 ülseratif kolit ve 25 Crohn hastalığı tanılı vaka çalışmaya dahil edildi. Crohn hastalığı için aktiviteyi belirlemede Crohn Hastalığı Aktivite İndeksi (CDAI), ülseratif kolit için ise Truelove-Witts indeksi kullanıldı. Bulgular: Sağlıklı grupla kıyaslandığında, sTREM-1 molekülü, İBS hastalarında anlamlı derecede düşük saptandı. Ülseratif kolit, Crohn hastalığı ve sağlıklı grup arasında sTREM-1 molekülü kıyaslandığında ise fark istatiksel olarak anlamlıydı. Aktif ve remisyonda olan hastalarda sTREM-1 düzeylerinde önemli bir fark bulunmamıştır. sTREM-1 seviyeleri C-reaktif protein, nötrofil- lenfosit oranı ve hemoglobin düzeyleri ile negatif korelasyon gösterdi. Sonuç: sTREM-1 seviyeleri İBS’de sağlıklı bireylere göre daha düşüktür. İBS tanısı için yararlı olabilir. Ancak, İBS’de hastalık aktivitesinin belirlemede doğru bir belirteç gibi görünmemektedir ve bu hastalarda hastalığın aktivitesini değerlendirmek için önerilemez.

Anahtar Kelimeler

sTREM-1, inflamatuar barsak hastalıkları, Crohn hastalığı, ülseratif kolit

Kaynakça

• 1. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000;164(10):4991-5. [CrossRef]
• 2. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55(3):426-31. [CrossRef]
• 3. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 2007;8(4):171-8. [CrossRef]
• 4. Bassyouni IH, Fawzi S, Gheita TA, Bassyouni RH, Nasr AS, El Bakry SA, et al. Clinical Association of a Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) in Patients with Systemic Lupus Erythematosus. Immunol Invest 2017;46(1):38-47. [CrossRef]
• 5. Liu M, Wu W, Zhao Q, Feng Q, Wang W. High expression levels of Trigger Receptor Expressed on Myeloid Cells-1 on neutrophils associated with increased severity of acute pancreatitis in mice. Biol Pharm Bull 2015;38(10):1450-7. [CrossRef]
• 6. Essa ES, Elzorkany KM. sTREM-1 in patients with chronic kidney disease on hemodialysis. APMIS 2015;123(11):969- 74. [CrossRef]
• 7. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70(3):439-44. [CrossRef]
• 8. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2(4947):1041-8. [CrossRef]
• 9. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25(3):247-55. [CrossRef]
• 10. Tzivras M, Koussoulas V, Giamarellos-Bourboulis EJ, Tzivras D, Tsaganos T, Koutoukas P, et al. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. World J Gastroenterol 2006;12(21):3416-9. [CrossRef]
• 11. Park JJ, Cheon JH, Kim BY, Kim DH, Kim ES, Kim TI, et al. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig Dis Sci 2009;54(7):1525-31. [CrossRef]
• 12. Billioud V, Gibot S, Massin F, Oussalah A, Chevaux JB, Williet N, et al. Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn’s disease. Dig Liver Dis 2012;44(6):466-70. [CrossRef]
• 13. Radsak MP, Taube C, Haselmayer P, Tenzer S, Salih HR, Wiewrodt R, et al. Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol 2007;2007:52040. [CrossRef]
• 14. Yasuda T, Takeyama Y, Ueda T, Shinzeki M, Sawa H, Takahiro N, et al. Increased levels of soluble triggering receptor expressed on myeloid cells-1 in patients with acute pancreatitis. Crit Care Med 2008;36(7):2048-53. [CrossRef]
• 15. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001;410(6832):1103-7. [CrossRef]
• 16. Schultsz C, Van Den Berg FM, Ten Kate FW, Tytgat GN, Dankert J. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 1999;117(5):1089-97. [CrossRef]
• 17. Brazil JC, Louis NA, Parkos CA. The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory bowel disease. Inflamm Bowel Dis 2013;19(7):1556-65. [CrossRef]